Loading...
XKRX065660
Market cap128mUSD
Jan 08, Last price  
19,300.00KRW
1D
0.78%
1Q
29.97%
Jan 2017
-18.57%
IPO
-50.13%
Name

Anterogen Co Ltd

Chart & Performance

D1W1MN
XKRX:065660 chart
P/E
—
P/S
28.89
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
2.52%
Rev. gr., 5y
12.50%
Revenues
6.50b
-1.38%
1,834,279,9603,532,247,7704,896,068,2605,357,319,2403,607,167,1704,147,568,0204,151,233,4708,121,552,7006,591,010,7906,500,249,530
Net income
-2.84b
L-58.45%
-1,415,653,390-58,309,090371,659,590446,737,570-961,759,730-4,049,844,880-4,375,063,260-553,984,070-6,837,097,540-2,840,849,743
CFO
-1.99b
L+0.65%
-1,010,252,750844,493,920-130,648,830379,205,990-1,504,760,530-1,648,844,500-4,414,918,170-3,045,351,650-1,975,372,510-1,988,220,126

Profile

Anterogen.Co.,Ltd., a bio-venture company, engages in the research, development, and commercialization of stem cell therapy products using adipose-derived stem cells in South Korea and internationally. The company offers medicines, including Cupistem injection, an adipose stem cell product that is used for the treatment of Crohn's fistula; Queencell, a stromal vascular fraction used for the regeneration of subcutaneous adipose tissue; and Remodulin injection, a medicine for the treatment of pulmonary arterial hypertension. It also provides cosmetics, such as hair care products comprising SCM2 and SCM2-Black; and skin care products, such as Therastem-Derma, Therastem-White Silk, and Therastem-White Glutathione, as well as human stem cell conditioned media, a cosmetic raw material. In addition, the company offers cell banking services; and analysis services that include sample analysis for clinical studies, as well as conducts biopharmaceutical tests for identification, purity, potency, adventitious virus, etc. Anterogen.Co.,Ltd. was founded in 2000 and is headquartered in Seoul, South Korea.
URL
http://anterogen.com/
IPO date
Feb 15, 2016
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
6,500,250
-1.38%
6,591,011
-18.85%
Cost of revenue
9,948,712
9,754,405
Unusual Expense (Income)
NOPBT
(3,448,462)
(3,163,395)
NOPBT Margin
Operating Taxes
3
(12,967)
Tax Rate
NOPAT
(3,448,462)
(3,150,427)
Net income
(2,840,850)
-58.45%
(6,837,098)
1,134.17%
Dividends
Dividend yield
Proceeds from repurchase of equity
7,457
BB yield
-0.01%
Debt
Debt current
9,740,400
12,711,149
Long-term debt
Deferred revenue
Other long-term liabilities
478,101
331,804
Net debt
(104,770,071)
(60,094,898)
Cash flow
Cash from operating activities
(1,988,220)
(1,975,373)
CAPEX
(149,818)
(1,480,810)
Cash from investing activities
4,511,636
(4,905)
Cash from financing activities
(5,000,000)
(1,011,822)
FCF
11,199,646
31,365,150
Balance
Cash
50,333,701
40,902,717
Long term investments
64,176,770
31,903,331
Excess cash
114,185,458
72,476,497
Stockholders' equity
(3,294,279)
10,906,014
Invested Capital
142,957,717
108,928,324
ROIC
ROCE
EV
Common stock shares outstanding
9,731
9,686
Price
17,090.00
16.26%
14,700.00
-77.14%
Market cap
166,309,165
16.80%
142,383,759
-76.24%
EV
61,539,094
82,288,861
EBITDA
(2,618,093)
(2,400,300)
EV/EBITDA
Interest
1,526,036
1,694,506
Interest/NOPBT